Pharmacological BH3 mimetics, such as venetoclax (a BCL-2-selective inhibitor) and navitoclax (a dual BCL-2/BCL-xL inhibitor), directly trigger MOMP and have achieved remarkable clinical efficacy in hematologic malignancies, including chronic lymphocytic leukemia and acute myeloid leukemia (173, 174). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.